Michael Gelband’s Xeris Biopharma Holdings XERS Stock Holding History

Michael Gelband’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,685	Closed	-$149K	–	2140
2026 Q1	$149K	Buy	+25,685	New	+$170K	﹤0.01%	1410
2025 Q4	–	Sell	-86,920	Closed	-$708K	–	2137
2025 Q3	$708K	Buy	+86,920	New	+$577K	0.01%	1077
2024 Q4	–	Sell	-84,740	Closed	-$242K	–	2128
2024 Q3	$242K	Buy	+84,740	New	+$218K	﹤0.01%	1419
2023 Q4	–	Sell	-185,221	Closed	-$345K	–	2119
2023 Q3	$345K	Buy	+185,221	New	+$424K	﹤0.01%	1378
2022 Q4	–	Sell	-20,528	Closed	-$32K	–	2203
2022 Q3	$32K	Sell	20,528 -36,266	-64%	-$60K	﹤0.01%	1803
2022 Q2	$87K	Sell	56,794 -453,164	-89%	-$956K	﹤0.01%	1756
2022 Q1	$1.3M	Buy	509,958 +469,564	+1,162%	+$1.15M	0.02%	990
2021 Q4	$118K	Buy	+40,394	New	+$87.3K	﹤0.01%	1929
2020 Q4	–	Sell	-16,867	Closed	-$100K	–	2434
2020 Q3	$100K	Sell	16,867 -15,715	-48%	-$62.8K	﹤0.01%	1589
2020 Q2	$87K	Buy	+32,582	New	+$113K	﹤0.01%	1647
2020 Q1	–	Sell	-47,000	Closed	-$331K	–	1700
2019 Q4	$331K	Buy	+47,000	New	+$388K	0.01%	1101

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Michael Gelband's XERS Position: Q2 2026 in Review

Michael Gelband sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 25,685 shares — an estimated $149K sold.

Michael Gelband first reported a position in XERS in Q4 2019 and held it in 11 quarters. The position peaked at $1.3M in Q1 2022. 237 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Michael Gelband reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 25,685 Xeris Biopharma Holdings shares in Q2 2026, an estimated $149K.
Michael Gelband first reported a position in Xeris Biopharma Holdings in Q4 2019 and held it in 11 quarters.
Michael Gelband's Xeris Biopharma Holdings position peaked at $1.3M in Q1 2022.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.